Adding ezetimibe to statin treatment: Is LDL-C lowering the only benefit?

Future Cardiology

Volumn 8, Issue 6, 2012, Pages 813-817

  Kostapanos, Michael S ^a   Mikhailidis, Dimitri P ^b   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b Department of Clinical Biochemistry   (United Kingdom)

Author keywords

atherosclerosis; atorvastatin; combination; coronary heart disease; dyslipidemia; ezetimibe; statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; ADD ON THERAPY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; IN-STENT RESTENOSIS; INSULIN RELEASE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; META ANALYSIS (TOPIC); PARTICLE SIZE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK REDUCTION;

EID: 84870199517     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.12.64     Document Type: Article

References (45)

1. Arimura T, Miura S, Ike A et al. Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina. J. Cardiol. 60(2), 111-118 (2012).
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934), 1383-1389 (1994).
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339(19), 1349-1357 (1998).
4. Kostapanos MS, Milionis HJ, Elisaf MS. An overview of the extra-lipid effects of rosuvastatin. J. Cardiovasc. Pharmacol. Ther. 13(3), 157-174 (2008).
5. Larosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14), 1425-1435 (2005). (Pubitemid 40471450)
6. Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294(19), 2437-2445 (2005). (Pubitemid 41627921)
7. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350(15), 1495-1504 (2004). (Pubitemid 38477774)
8. Catapano AL, Reiner Z, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217(1), 3-46 (2011).
9. Kostapanos MS, Athyros VG, Karagiannis A, Mikhailidis DP. Therapeutic options for statin-intolerant patients. Curr. Med. Res. Opin. 28(3), 345-349 (2012).
10. Kostapanos MS, Elisaf MS, Mikhailidis DP. Targeting cardiovascular risk: the impact of age, gender and compliance to treatment. Curr. Med. Res. Opin. 28(9), 1415-1419 (2012).
11. Liberopoulos EN, Florentin M, Mikhailidis DP, Elisaf MS. Compliance with lipidlowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin. Drug Saf. 7(6), 717-725 (2008).
12. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc. Health Risk Manag. 8, 415-427 (2012).
13. Mikhailidis DP, Lawson RW, McCormick AL et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr. Med. Res. Opin. 27(6), 1191-1210 (2011).
14. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Metaanalysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr. Med. Res. Opin. 23(8), 2009-2026 (2007). (Pubitemid 47300401)
15. Robinson JG, Ballantyne CM, Hsueh W et al. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J. Clin. Lipidol. 5(6), 474-482 (2011).
16. Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic effects of ezetimibe: do they really exist? Eur. J. Pharmacol. 633(1-3), 62-70 (2010).
17. Kostapanos MS, Spyrou AT, Tellis CC et al. Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress. Lipids 46(4), 341-348 (2011).
18. Lioudaki E, Ganotakis ES, Mikhailidis DP. Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Curr. Vasc. Pharmacol. 9(1), 62-86 (2011).
19. Davis HR Jr, Lowe RS, Neff DR. Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis 215(2), 266-278 (2011).
20. Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358(14), 1431-1443 (2008). (Pubitemid 351482735)
21. Paraskevas KI, Veith FJ, Mikhailidis DP. Carotid intima-media thickness and ezetimibe: the end of a misunderstanding? Curr. Vasc. Pharmacol. 9(4), 381-384 (2011).
22. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291(9), 1071-1080 (2004). (Pubitemid 38541684)
23. Fleg JL, Mete M, Howard BV et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J. Am. Coll. Cardiol. 52(25), 2198-2205 (2008).
24. Meaney A, Ceballos G, Asbun J et al. The VYtorin on Carotid intima-media Thickness and Overall arterial Rigidity (VYCTOR) study. J. Clin. Pharmacol. 49(7), 838-847 (2009).
25. Kostapanos MS, Katsiki N, Elisaf MS, Mikhailidis DP. Editorial: reducing cardiovascular risk: is low-density lipoproteincholesterol (LDL-C) lowering enough? Curr. Vasc. Pharmacol. 10(2), 173-177 (2012).
26. Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32(11), 1345-1361 (2011).
27. Itakura H, Nakaya N, Kusunoki T et al. Long-term event monitoring study of fluvastatin in Japanese patients with hypercholesterolemia: efficacy and incidence of cardiac and other events in elderly patient (>/= 65 years old). J. Cardiol. 57(1), 77-88 (2011).
28. Morishita R, Itakura H, Nakaya N et al. Ris factors for cardiovascular events in Japanese patients treated with fluvastatin from the long-term event monitoring (LEM) study. Curr. Vasc. Pharmacol. 10(2), 178-186 (2012).
29. Lee SH, Park S, Kang SM, Jang Y, Chung N Choi D. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipidemia. J. Cardiovasc. Pharmacol. Ther. 17(1), 65-71 (2012).
30. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or canno get to the low density lipoprotein cholesterol target despite taking a statin. Curr. Med. Res Opin. 23(9), 2183-2192 (2007). (Pubitemid 350246604)
31. Migdalis I, Efthimiadis A, Pappas S, Alexopoulos D, Vlasserou F, Mikhailidis DP Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr. Med. Res. Opin. 25(10), 2571-2576 (2009).
32. Mikhailidis DP, Elisaf M, Rizzo M et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr. Vasc. Pharmacol. 9(5), 533-571 (2011).
33. Mikhailidis DP, Elisaf M, Rizzo M et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr. Vasc. Pharmacol. 9(5), 531-532 (2011).
34. Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur. J. Pharmacol. 590(1-3), 327-332 (2008).
35. Kostapanos MS, Milionis HJ, Filippatos TD et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin. Ther. 29(7), 1403-1414 (2007). (Pubitemid 47348117)
36. Kalogirou M, Tsimihodimos V, Gazi I et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr. Med. Res. Opin. 23(5), 1169-1176 (2007). (Pubitemid 46799601)
37. Kalogirou MTV, Saougos V, Lagos K, Tselepis AD, Elisaf M. Effect of ezetimibe on lipoprotein subfraction concentrations: the role of atorvastatin pretreatment. Arch. Med. Sci. 3, 344-350 (2007). (Pubitemid 351212283)
38. Goldfine AB. Statins: is it really time to reassess benefits and risks? N. Engl. J. Med. 366(19), 1752-1755 (2012).
39. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 32(10), 1924-1929 (2009).
40. Preiss D, Seshasai SR, Welsh P et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305(24), 2556-2564 (2011).
41. Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS. Do statins beneficially or adversely affect glucose homeostasis? Curr. Vasc. Pharmacol. 8(5), 612-631 (2010).
42. Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int. J. Clin. Pract. 63(9), 1308-1313 (2009).
43. Hiramitsu S, Miyagishima K, Ishii J et al. The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J. Cardiol. (2012) (In Press).
44. Moutzouri E, Liberopoulos E, Mikhailidis DP et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int. J. Clin. Pract. 65(11), 1141-1148 (2011).
45. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebocontrolled trial. Lancet 377(9784), 2181-2192 (2011).